NZ Lung Cancer Research Review Issue 19

In this issue:

Trastuzumab deruxtecan in HER2-mutant NSCLC
SAKK 16/14: durvalumab plus chemotherapy in early-stage NSCLC
NIVORAD: nivolumab and SABR in advanced NSCLC
Lung-MAP S1400I: nivolumab plus ipilimumab in squamous cell lung cancer
IMpower010: adjuvant atezolizumab in resected NSCLC
Postdiagnosis smoking cessation: risk of lung cancer progression
Does MDM discussion influence palliative care referrals?
Survival improvements linked to treatment pattern changes
Lung cancer surgery: a model for international benchmarking
Optimal method of mediastinal assessment of lung cancer

Please login below to download this issue (PDF)